Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Ex-Pfizer exec Schulman lands at Polaris after an abrupt departure

Months after a swift exit from Pfizer's highest ranks, Amy Schulman has made her next move, joining high-profile biotech investor Polaris as a venture partner

Merck whacks 600 sales reps as part of 8,500 bloodletting

Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed

Sarepta science officer Krieg 'terminated' quietly

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

News flash for biopharma bosses: More than half your employees want to leave

Biopharma employee looking for a new job? You're not alone. In fact, you're not even in the minority, a new report says.

Merck KGaA brings on U.S. Merck's Rossetti to head R&D

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Teva's picked its next chairman, rebel investor Landa says--and he's not in favor

Controversial Teva chairman Phillip Frost may not be leaving until the end of this year, but the company already has its next chairman lined up. That's according to one of the company's activist investors. And he doesn't much like its pick.

Vertex's Mueller steps down from R&D position

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Philips Healthcare chief DiSanzo out in management shakeup

The chief of Philips Healthcare, Deborah DiSanzo, has left the company ahead of what is expected to be disappointing Q2 earnings. The unit will now report directly to CEO Frans van Houten, The Wall Street Journal reported.

Baxter gets C-suite lined up ahead of pharma spinoff

Baxter has tapped a couple of new execs for the biopharma unit it plans to spin off next year. And with new competition in one of the division's bigger markets, its new leaders could have their work cut out for them.

Merck vet steps in to lead Third Rock's immuno-oncology upstart

Third Rock Ventures partner Cary Pfeffer is stepping aside as the start-up CEO at Jounce Therapeutics in favor of Merck veteran Richard Murray.